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Supplementary Materials Results
The twelve markers identified in this study were taken forward into another independent study of prostate cancer FFPE biopsy samples to develop a locked down model for clinical use (manuscript submitted). In this new study, we identified the best marker subset of the 12 markers and locked the resulting 8-marker model down, containing the following biomarkers: SMAD4, FUS, CUL2, YBX1, DERL1, PDSS2, HSPA9 and pS6. In the interest of completeness, we analyzed this set of markers on the TMA samples in this study, with the understanding that the TMA cohort contributed to the marker selection process. We again used the same patient partition, and trained on the L TMA followed by testing on both L TMA and H TMA samples.
We analyzed 268 patients containing 40 dead-from-disease events. The resulting test AUC based on L TMA for prediction of aggressive disease was 0.64 (95% CI: 0.56-0.71) with a test odds ratio for aggressive disease of 13 per unit change in risk score (95% CI: 2.3-341). The test hazard ratio for lethal outcome prediction was 14 per unit change in risk score (95%CI: 1.3-393). To confirm the ability to generalize across sampling error, the model derived from L TMA train was also tested on the test H TMA with consistent results for both indications. The H TMA test AUC was 0.70 (95% CI: 0.62-0.78) with an odds ratio for aggressive disease of 46 per unit change in risk score (95% CI: 5.6-1290). The H TMA test hazard ratio for prediction of lethal outcome was 19 per unit change in risk score (95% CI: 1.4-620).
Materials and Methods

Generation of TMA blocks
TMA blocks were prepared using a modified agarose block procedure (Yan et al, 2007) . To generate the test TMA (MPTMA10), we selected 72 FFPE tissue blocks of prostatectomy samples with available annotations for GS and pathological stage. Of these, 37 had a GS of 3 + 3 = 6 with T2 stage, while 35 had a GS of 4 + 3 = 7 or a GS of either 3 + 3 = 6 or 3 + 4 = 7 with T3b stage. One 1 mm core per patient sample was taken from areas of lowest Gleason pattern and placed into an acceptor block.
For construction of H and L TMAs, we used the cohort of FFPE human prostate cancer tissue blocks with clinical annotations and long-term patient outcome information. For each patient sample, a core was taken from an area with the highest Gleason pattern and deposited into an H acceptor block. A second core was then taken from an area with the lowest Gleason pattern and put into an L acceptor block. The order of sample core placement into H block was randomized, and core positions in the L block were identical to those in the H block. In addition, cores from FFPE blocks of cell-line controls (Table S5) were placed in the upper and lower parts of all H and L TMA blocks. Upon completion, 5 μm serial sections were cut from each block and representative sections were stained with H&E and scanned with the ScanScope XT system.
Images of H&E-stained cores were then independently annotated for observed Gleason pattern by a board-certified anatomical pathologist in a blinded manner.
The resulting H and L TMA blocks were identical for a set of patient samples, but differed in observable Gleason pattern (Figure 1 , bottom). For this study, two pairs of TMA blocks (MPTMAF5H and 5L, 6H and 6L) were generated with cores from 380 patient samples.
Biomarker selection
To identify biomarkers for prostate cancer aggressiveness, we developed a selection and evaluation process that could be broadly applicable across diseases and conditions. The process, shown in Figure 2 , had biological, technical, performance and validation stages.
In the biological stage, an initial list of potential biomarkers for prostate cancer aggressiveness was compiled from publically available data. The list was then prioritized based on biological relevance, in silico analysis, review of the Human Protein Atlas (www.proteinatlas.org), and commercial availability of requisite MAbs. Biological relevance review was based on mechanism of action in cells and, in particular, in the disease. In silico analysis was based on previously known gene amplifications, deletions and mutations, and univariate performance or progression correlation between these genetic alterations and the disease. The Human Protein Atlas contains data on protein expression levels in various tissues across disease states.
In the technical stage, commercial MAbs were obtained and tested for their ability to detect biomarkers from clinical samples. Initially, we stained samples of malignant and benign prostatic tissue using a DAB-based IHC staining procedure and selected candidate antibodies that exhibited a good signal:noise ratio and were specific for epithelial cell staining. We further tested successful candidates on malignant and benign prostatic tissue samples using IF along with region-of-interest markers, epithelial cytokeratins CK8 and CK18 and basal markers CK5 and Trim29, as described (Supplementary Materials and Methods). Antibodies and biomarkers that met the IF criteria were taken forward to the performance stage.
In the performance stage, MAbs were tested on TMAs. Performance was evaluated for a univariate correlation between tumor epithelium expression and disease state. The MAbs and biomarkers that demonstrated univariate correlation between expression and disease state were then evaluated on a larger H and L TMA set for both univariate correlation and performance in combination with other markers.
The quantitative multiplex immunofluorescence (QMIF) staining procedure
The QMIF was composed of two initial blocking steps followed by four MAb incubation steps with appropriate washes in between. Blocking consisted of biotin blocking steps followed by treatment with Sniper reagent (Biocare Medical), according to the manufacturer's instructions.
The first MAb incubation step consisted of a mixture of anti-biomarker 1 mouse MAb and anti-biomarker 2 rabbit MAb, followed by a second step containing a mixture of anti-mouse IgG Fab-fluorescein isothiocyanate (FITC) and anti-rabbit IgG Fab-biotin. A third "visualization" step included a mixture of anti-FITC MAb-Alexa 568, streptavidin-Alexa 633, as well as MAbs against epithelium (anti-CK8-Alexa 488 and anti-CK18-Alexa 488) and basal epithelium (anti-CK5-Alexa 555 and anti-Trim29-Alexa 555), respectively. A final, fourth step comprised a brief incubation with 4ʹ,6-diamidino-2-phenylindole (DAPI) for nuclear staining. After final washes, slides were mounted with Prolong Gold™ (Life Technologies) before coverslips were added.
Slides were kept permanently at -20°C before and after imaging.
For diaminobenzidine (DAB)-based IHC staining, slides with tissue were processed as described above, blocked with Sniper reagent™ (Biocare Medical) and incubated with primary antibody solution. UltraVision (Thermo Scientific) was used as a secondary reagent. Finally, tissue was counterstained with hematoxylin and coverslips were added.
FFPE tissue block quality evaluation
A 5 μm section from each FFPE block was manually stained with anti-phospho STAT3(T705) rabbit MAb, anti-STAT3 mouse MAb and region-of-interest markers, as described above. Slides were visually examined under a fluorescence microscope. Based on the staining intensities and autofluorescence, the sections and their corresponding FFPE blocks were graded into four quality categories.
Image acquisition
Two Vectra Intelligent Slide Analysis Systems (PerkinElmer) were used for automated image acquisition as described elsewhere. DAPI, FITC, tetramethylrhodamine isothiocyanate (TRITC) and Cy5 long pass filter cubes were optimized for maximal multiplexing capability. Vectra 2.0 and Nuance 2.0 software packages (PerkinElmer) were used for automated image acquisition and development of the spectral library, respectively.
TMA acquisition protocols were run in an automated mode according to the manufacturer's instructions (PerkinElmer). Two 20× fields per core were imaged using a multispectral acquisition protocol that included consecutive exposures with DAPI, FITC, TRITC and Cy5 filters. For maximal reproducibility, light source intensity was adjusted with the help of an XCite Optical Power Measurement System (Lumen Dynamics) before image acquisition for each TMA slide. Identical exposure times were used for all slides containing the same antibody combination. A set of TMA slides stained with the same antibody combinations was imaged on the same Vectra microscope.
A spectral profile was generated for each fluorescent dye as well as for FFPE prostate tissue autofluorescence. Interestingly, two types of autofluorescence were observed in FFPE prostate tissue. A typical autofluorescence signal was common in both benign and tumor tissue, whereas an atypical "bright" type of autofluorescence was specific for bright granules present mostly in epithelial cells of benign tissue. A spectral library containing a combination of these two spectral profiles was used to separate or "unmix" individual dye signals from the autofluorescent background.
Definiens automated image analysis
We developed an automated image analysis algorithm using Definiens Developer XD for tumor identification and biomarker quantification. For each 1.0 mm TMA core, two 20× image fields were acquired. The Vectra multispectral image files were first converted into multilayer TIFF files using inForm (PerkinElmer) and a customized spectral library, and then converted to singlelayer TIFF files using BioFormats (OME). The single-layer TIFF files were imported into the Definiens workspace using a customized import algorithm so that, for each TMA core, both of the image field TIFF files were loaded and analyzed as "maps" within a single "scene".
Autoadaptive thresholding was used to define fluorescent intensity cut-offs for tissue segmentation in each individual tissue sample in our image analysis algorithm. Cell-line control cores within the TMA were automatically identified in the Definiens algorithm based on predefined core coordinates. The tissue samples were segmented using the fluorescent epithelial and basal cell markers, along with 4ʹ,6-diamidino-2-phenylindole (DAPI) for classification into epithelial cells, basal cells, and stroma, and further compartmentalized into cytoplasm and nuclei.
Individual gland regions were classified as malignant or benign based on the relational features between basal cells and adjacent epithelial structures combined with object-related features, such as gland thickness. Epithelial markers are not present in all cell lines, therefore the cell-line controls were segmented into tissue versus background using the autofluorescence channel.
Fields with artifact staining, insufficient epithelial tissue, or out-of-focus images were removed by a rigorous multi-parameter quality-control algorithm.
Epithelial marker and DAPI intensities were quantified in malignant and nonmalignant epithelial regions as quality-control measurements. Biomarker intensity levels were measured in the cytoplasm, nucleus, or whole cell in the malignant tissue based on predetermined subcellular localization criteria. The mean biomarker pixel intensity in the malignant compartments was averaged across the maps with acceptable quality parameters, to yield a single value for each tissue sample and cell line control core.
Univariate analysis of aggressiveness and lethality
Our objectives for univariate analysis were twofold: to characterize univariate behavior as a performance assessment for potential inclusion in the final marker set, and to provide a reduced set of markers for exhaustive multivariable model exploration. All modeling was done in R 3.0 using standard functions and packages, including glm, survival, KMsurv, binom, and pROC.
Biomarkers were assessed based on two outcomes: prediction of Surgical GS and prediction of death (lethality). Prediction of Surgical GS, categorized as indolent or more severe, was modeled with both ORs (logistic regression) and biomarker means (linear regression). Lethality was modeled using HRs (traditional Cox proportional hazards), ORs (logistic regression), and marker means (linear regression). In addition, to provide nonparametric and robust assessments, Wilcoxon and permutation tests were applied. Figure 3 shows the key results. Univariate results were also directly considered in selection of the final marker set, as seen in Figure 5 .
Biomarker ranking for aggressiveness via exhaustive search of multimarker models
We sought to rank the biomarkers by importance in multimarker models; 31 biomarkers, refined from the original set of 39 to improve technical performance further, were used in an exhaustive biomarker search. We considered all combinations of up to five biomarkers from the 31 biomarkers tested in the L TMA in the H and L TMA analysis. For each biomarker combination, 500 training sets were generated by bootstrapping, and associated complementary test sets were obtained. A logistic regression model was applied to each training set and then tested on each of the associated test sets. Training and test AUC (i.e. C statistic) and training AIC were obtained in each round. Medians and 95% CIs were obtained for all three statistics.
We then considered biomarker selection frequency in the models and sorted them by their AIC and, separately, by their test AUC. For each of the resulting rankings of the models, the frequency of biomarker utilization in the top 1% and the top 5% of the lists was determined. The biomarkers that were included in at least 50% of models were then identified. Table S2 shows biomarker frequency in the prediction of aggression assessment. The performance of the top-ranking models was similar. Moreover, the number of biomarkers in the top-ranking models varied. To resolve this issue, which appeared to relate to model size, we considered the top 1% of the models sorted by test AUC. We studied the resulting distributions for a number of different population assumptions, including cases where intermediate core GSs were excluded from analysis, or were included with indolent scores, or were included with high scores. In the final analysis, we concluded that an eight-biomarker model provided the best tradeoff between performance and complexity in this experimental data set.
FFPE cell-line controls
Selected cell lines were grown in standard conditions with and without treatment before harvesting as indicated (Table S5) . Cells were washed with phosphate-buffered saline (PBS), fixed directly on plates with 10% formalin for 5 min, then scraped and collected in PBS with continued fixation at room temperature for 1 hour. Cells were washed twice with PBS, resuspended in Histogel (Thermo Scientific) at 70°C and quickly spun down in a1.5 ml microfuge tube to form a condensed cell-Histogel pellet. The pellets were then embedded in paraffin and placed into standard paraffin blocks that served as donor blocks for TMA construction. DU145 cells with inducible knock down of CCND1 and SMAD4 were established according to manufacturer's instructions using the 'Tet-one' system (Clontech).
Antibody specificity assays
Several MAbs, including anti-ACTN1, anti-CUL2, anti-Derlin1, anti-FUS, anti-PDSS2, anti-SMAD2, anti-VDAC1, anti-YBX1, and anti-HSPA9, were validated by Western blotting (WB) and immunohistochemistry (IHC) assay of target-specific knockdown and control cells ( Figure   S1 ). Details of the small interfering RNA (siRNA) sequences and host cell lines are listed in Table S6 . Cells were seeded into 12-well plates and transfected with 25 nM of siRNAs and DharmaFect transfection reagent (Thermo Scientific Dharmacon); mock transfection included only the transfection reagent. Cells transfected with two nontargeting sequences were also included as controls.
For WB assay, transfected cells were harvested at 72 hours and lyzed with Pierce RIPA buffer (Thermo Scientific) supplemented with Halt protease inhibitor cocktail (Thermo Scientific).
Protein concentration was measured using Pierce BCA reagent (Thermo Scientific). Samples were adjusted to equal protein concentrations and then mixed with sample buffer (Boston BioProducts) and run on precast Criterion TGX 4-15% SDS-PAGE gels (Bio-Rad). The samples were transferred onto PVDF or nitrocellulose membranes using the IBlot apparatus (Life Technologies), and immunoblotted with antibodies at 4°C overnight, followed by incubation with secondary mouse or rabbit MAbs (Sigma Aldrich). The blots were developed with SuperSignal West Femto reagents (Thermo Scientific), and visualized by exposure to the FluorChem Q system (Protein Simple).
For the IHC assay, cells grown on coverslips in a 12-well plate were fixed with methanol on ice for 20 min at 72 hours post-transfection. This was followed by permeabilization with 0.2% Triton X-100 on ice for 10 min. UltraVision LP Detection System HRP Polymer/DAB Plus Chromogen Kit (Thermo Scientific) was used for the subsequent IHC assay according to the manufacturer's instructions.
The SMAD4 antibody was validated by WB and IHC assays of the SMAD4-positive cell line PC3 and the SMAD4-negative cell line BxPC3. The phospho-S6 antibody was validated by WB and IHC of naïve and LY294002-treated DU145 cells.
Cell proliferation assay
HeLa cells were transiently transfected with two nontargeting siRNAs as well as si9-11, specific for HSPA9 (see Table S6 for details of siRNA sequences). Cells were replated 48 hours after transfection and seeded in triplicate at 1000 cells per well in a 96-well plate. Cell proliferation was monitored using a CellTiter-Glo® Luminescent Cell Viability Kit (Promega) according to the manufacturer's instructions at 0, 24, 72 and 120 hours after replating.
Clonogenic assay
At 48 hours post-transfection, HeLa cells were replated at 500 cells per well in a 6-well plate with 2 ml of cell medium. The cells were fixed with Crystal Violet Solution (Sigma) 7 days after plating. The images of each well were captured using AlphaView software in the FluorChem Q system (Protein Simple) and processed using ImageJ software.
Cell vitality assay
HeLa cells were harvested at 120 hours post-transfection. Cells were collected using trypsin. The cell pellets from each well of a 12-well plate were suspended in 500 µl of cell medium. Cell suspension (95 µl) was mixed with 5 µl of Solution 5 (VB-48/PI/AO), and 30 µl of the mixture was loaded onto an NC-Slide A2 (both from ChemoMetec). Cell vitality was measured by a NucleoCounter NC-3000™ (ChemoMetec) according to the manufacturer's instructions.
Caspase assay
HeLa cells were harvested at 120 hours after siRNA transfection using trypsin. Cells were suspended at 2×10 6 cells/ml. An aliquot of 93 µl of the cell suspension was mixed with 5 µl diluted FLICA reagent (ImmunoChemistry Technologies) and 2 µl of Hoechst 33342 (Life Technologies). The mixture was incubated at 37°C for 1 hour. HeLa cells were washed twice with 1× Apoptosis Buffer (ImmunoChemistry Technologies). The cell pellets were suspended in 100 µl 1× Apoptosis Buffer and 2 µl of propidium iodide. A 30 µl aliquot of the mixture was loaded onto an NC-Slide A2 and read using NucleoCounter NC-3000 software for caspase assay.
Cells positive for FLICA staining were counted as apoptotic cells.
Identification of HSPA9 (Mortalin)
For identification of the Leica "anti-DCC" antibody target ( Figure S1 ), a preparative immunoprecipitation was performed. Ten p100 plates of confluent A549 cells were harvested with 5 ml of RIPA buffer (Thermo Scientific) with added protease inhibitors. The cell lysate was spun down at 14,000 rpm for 5 min; the supernatant was heated for 5 min at 80°C, then chilled on ice, and spun down again at 14,000 rpm for 5 min. Supernatant was collected and, after addition of 50 µl of Protein A/G beads (Thermo Scientific) with 2 µg of pre-bound "anti-DCC"
antibody, was incubated with rocking at 4°C for 2 hours. Beads were washed three times with TBS + 1% Triton X100, and boiled with 30 µl of 1× SDS-PAGE loading buffer. Supernatant was loaded onto a 10% SDS-PAGE gel, and separated under standard SDS-PAGE conditions. The gel was stained with a silver stain kit for mass spectrometry (Thermo Scientific); the specific band was cut out, digested with trypsin, and subjected to MS/MS sequencing mass spectrometry at the Taplin Mass Spectrometry Facility (Harvard Medical School). Identified peptides were aligned with Human Protein reference databases. The identified protein HSPA9 was further validated as described. Figure S1 . Table S2 . Performance-based biomarker ranking: aggressiveness. Combinations of up to five biomarkers were generated and tested for their ability to predict severe disease (aggressiveness).
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The frequency of each biomarker in the best models was used for ranking. 
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